The DFW Hospital Council (DFWHC) and Alexion Pharmaceuticals, Inc. webinar “Andexanet alfa Budget Impact Model” originally broadcast on May 26 has been posted online.

The panel discussion detailed an approved model structure developed with clinical guidance on the cost-effectiveness and budgetary impact of andexanet alfa on selected health outcomes and costs.

Speakers included Kelly McNeil-Posey, director of health economics and outcomes research at Alexion; and Sharon Williams, director of U.S. strategic accounts at Alexion.

You can view the video here.

For information, please contact Kelly McNeil-Posey at Kelly.McNeil-Posey@alexion.com; Sharon Williams at Sharon.Williams@alexion.com; Deena Flanigan Kreutzer at Deena.Kreutzer@alexion.com; or Dan Coburn at dan.coburn@alexion.com.